SURF
Surface Oncology Inc (SURF)
$0.9217
Market is closedMarket is closed – opens on 8 PM, 01 Dec 2022
– opens on 8 PM, 01 Dec 2022
Key Stats
$0.9
Day's Range
$0.97
$0.92
52-Week Range
$5.98
| Returns | |
| 1 month return | 24.1% |
| 3 month return | 32.78% |
| 1 year return | 83.69% |
| 5 year return | 92.94% |
Company Information
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
| Organization | Surface Oncology Inc |
| Employees | 67 |
| CEO | Dr. Robert W. Ross M.D. |
| Industry | Health Technology |
Analyst Recommendation
based on 5 analysts ratings
Buy
100%
Buy
0%
Hold
0%
Sell
Based on 5 Wall street analysts offering stock ratings for Surface Oncology Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 485.87%Current
$0.92
Target
$5.4
Recommendation Trend
Based on 5 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 5 | 11 | 11 |
| Hold | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Highlights
| Market Capitalization | 57.5M |
| Book Value | $1.86 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.23 |
| Wall Street Target Price | 5.4 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.54 |
| Enterprise Value | -29240739 |
| Enterprise Value/Revenue | 0.33 |
| Enterprise Value/Ebitda | 0.47 |
Technicals
| Beta | 1.71 |
| 50 Day MA | 1.1 |
| 200 Day MA | 1.91 |
Institutional Holdings
ARK Investment Management LLC
9.97%
EcoR1 Capital, LLC
6.48%
Atlas Venture Associates IX, LLC
4.87%
Vanguard Group Inc
3.81%
Citadel Advisors Llc
2.28%
Goldman Sachs Group Inc
2.09%
Discover more
Frequently Asked Questions
What is Surface Oncology Inc share price today?
Can Indians buy Surface Oncology Inc shares?
How can I buy Surface Oncology Inc shares from India?
Can Fractional shares of Surface Oncology Inc be purchased?
What are the documents required to start investing in Surface Oncology Inc stocks?
What are today’s High and Low prices of Surface Oncology Inc?
What are today’s traded volumes of Surface Oncology Inc?
What is today’s market capitalisation of Surface Oncology Inc?
What is the 52 Week High and Low Range of Surface Oncology Inc?
How much percentage Surface Oncology Inc is down from its 52 Week High?
How much percentage Surface Oncology Inc is up from its 52 Week low?
What are the historical returns of Surface Oncology Inc?
Who is the Chief Executive Officer (CEO) of Surface Oncology Inc?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*